Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Medtronic
McKesson
Harvard Business School

Last Updated: August 11, 2022

Investigational Drug Information for Fulranumab


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Fulranumab?

Fulranumab is an investigational drug.

There have been 4 clinical trials for Fulranumab. The most recent clinical trial was a Phase 3 trial, which was initiated on March 25th 2015.

The most common disease conditions in clinical trials are Osteoarthritis and [disabled in preview]. The leading clinical trial sponsors are Janssen Research & Development, LLC and [disabled in preview].

There are six US patents protecting this investigational drug and three hundred and seventeen international patents.

Recent Clinical Trials for Fulranumab
TitleSponsorPhase
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002Janssen Research & Development, LLCPhase 3
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003Janssen Research & Development, LLCPhase 3
Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001Janssen Research & Development, LLCPhase 3

See all Fulranumab clinical trials

Clinical Trial Summary for Fulranumab

Top disease conditions for Fulranumab
Top clinical trial sponsors for Fulranumab

See all Fulranumab clinical trials

US Patents for Fulranumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fulranumab See Plans and Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) See Plans and Pricing
Fulranumab See Plans and Pricing Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
Fulranumab See Plans and Pricing Cell culture medium LA JOLLA BIOLOGICS, INC. (San Diego, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Medtronic
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.